by Team Small News | Jan 22, 2026 | Dr Reddy's
Dr. Reddy’s Laboratories, a leading Indian pharmaceutical company, is shifting its focus towards biosimilars and a new weight-loss drug to drive growth as its exclusivity for the generic version of Revlimid in the US market is set to expire. Revlimid, a blood...
by Team Small News | Jan 21, 2026 | Dr Reddy's
KPI Green Energy Ltd. has reported impressive financial results for the third quarter, with a 39.4% year-over-year increase in net profit to ₹118 crore. The company’s revenue also saw a significant rise of 44.6% to ₹663 crore during the quarter. Additionally,...
by Team Small News | Jan 16, 2026 | Dr Reddy's
The Indian pharmaceutical industry is expected to experience a mixed bag in the third quarter of the year, with domestic formulations likely to counterbalance the pressure from pricing in the US market. The sector’s growth is anticipated to be driven by a strong...
by Team Small News | Jan 15, 2026 | Dr Reddy's
Dr. Reddy’s Laboratories has launched an over-the-counter (OTC) eye drop solution, Olopatadine Hydrochloride Ophthalmic Solution, in the US market. The solution is a generic equivalent of Extra Strength Pataday Once-Daily Relief, which is used to provide...
by Team Small News | Jan 13, 2026 | Dr Reddy's
Dr. Reddy’s Laboratories has received a Pre-Approval Inspection (PAI) letter from the US Food and Drug Administration (USFDA) for its biologics facility located in Hyderabad, India. This letter indicates that the USFDA has completed its inspection of the...
by Team Small News | Jan 7, 2026 | Dr Reddy's
Dr. Reddy’s Laboratories has launched Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus (HEV) infection in India. This vaccine is the only one approved by the Drug Controller General of India (DCGI) for active immunization against HEV...